Angiotensin III (human, mouse): Atomic Insights for Cardiovascular & Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) (CAS: 13602-53-4) is a biologically active hexapeptide central to the renin-angiotensin-aldosterone system (RAAS) and is used widely in cardiovascular and neuroendocrine research (Oliveira et al., 2025). This peptide retains full aldosterone-stimulating activity and mediates approximately 40% of angiotensin II’s pressor response, acting through both AT1 and AT2 receptors (t7-tag.com reference). APExBIO’s A1043 formulation offers high solubility and storage stability, supporting both in vitro and in vivo models (APExBIO product page). Recent evidence highlights its role in modulating receptor-specific responses and its potential relevance in viral pathogenesis models (Oliveira et al., 2025). This article details the atomic mechanisms, benchmarks, and experimental parameters for rigorous use of Angiotensin III (human, mouse) in research workflows.

Biological Rationale

Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe) is a RAAS peptide produced by N-terminal cleavage of angiotensin II via angiotensinase enzymes in erythrocytes and tissues (Oliveira et al., 2025). It is detected in both human and murine models and is highly conserved. As a core effector in the RAAS, Angiotensin III regulates blood pressure, fluid balance, and aldosterone release (angiotensin-ii.com article). The peptide is present at physiologically relevant concentrations in plasma and tissues, with activity modulated by local enzyme expression and receptor availability. Unlike longer angiotensin peptides, Angiotensin III demonstrates unique receptor specificity, engaging both AT1 and AT2 subtypes and modulating distinct signaling pathways. Its robust pressor and aldosterone-inducing effects make it an essential reagent for dissecting cardiovascular and neuroendocrine functions.

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III binds to both AT1 and AT2 angiotensin II receptors, with a relative preference for AT2 in some systems (t7-tag.com article). Upon receptor engagement, it induces intracellular calcium mobilization and activates downstream effectors, including protein kinase cascades. In vascular smooth muscle cells, Angiotensin III triggers vasoconstriction via AT1-mediated G-protein signaling, resulting in increased blood pressure. In the adrenal cortex, it stimulates aldosterone biosynthesis and secretion, maintaining electrolyte and fluid homeostasis. The peptide also suppresses renin release via negative feedback. In the central nervous system (rodent models), Angiotensin III elicits pressor (blood pressure-raising) and dipsogenic (thirst-inducing) responses (Oliveira et al., 2025), paralleling but not fully duplicating the effects of angiotensin II. Recent research shows that N-terminal deletions (resulting in Angiotensin III) enhance spike–AXL binding, with implications for viral pathogenesis (Oliveira et al., 2025).

Evidence & Benchmarks

• Angiotensin III mediates approximately 40% of the pressor activity of angiotensin II in vivo, while retaining full aldosterone-stimulating capacity (Oliveira et al., 2025).
• Exogenous Angiotensin III induces aldosterone secretion and suppresses plasma renin activity in rodent models at doses of 10–100 nM, with effects detectable within 15–30 minutes (t7-tag.com article).
• In vitro, Angiotensin III exhibits a molecular weight of 931.09 Da and a chemical formula of C46H66N12O9, with solubility ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO at 20°C (APExBIO product page).
• Binding studies demonstrate that Angiotensin III enhances spike–AXL interaction, indicating a role in modulating viral pathogenesis in addition to classical RAAS functions (Oliveira et al., 2025).
• Angiotensin III's dual receptor action enables more nuanced modeling of AT1 vs AT2 signaling compared to conventional RAAS peptides (angiotensin-ii.com article).

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is used in cardiovascular, renal, and neuroendocrine research to dissect RAAS function and receptor signaling. It is a valuable tool for hypertension models, aldosterone secretion assays, and studies of central dipsogenic responses. The peptide’s high solubility and receptor specificity enable reproducible experimental setups and troubleshooting (magnetic-co-ip.com reference). Unlike angiotensin II, Angiotensin III allows precise interrogation of AT2-mediated pathways. However, its activity profile does not fully replicate that of angiotensin II, particularly in certain vascular beds and species. Long-term storage in solution is not recommended, as stability may decrease above -20°C or in hydrated environments (APExBIO product page).

Common Pitfalls or Misconceptions

• Angiotensin III does not fully substitute for angiotensin II in all models; distinct receptor and tissue responses should be validated experimentally.
• Prolonged storage in aqueous solution (>24 hours at 4°C) leads to peptide degradation and loss of biological activity.
• AT2 receptor selectivity is relative, not absolute; off-target effects may occur at high concentrations.
• Pressor and aldosterone-inducing effects are dose-dependent and can vary by species and tissue type.
• Peptide modifications (phosphorylation, substitutions) can alter receptor binding and downstream signaling; only native sequence (Arg-Val-Tyr-Ile-His-Pro-Phe) is validated for standard assays.

Workflow Integration & Parameters

APExBIO’s Angiotensin III (SKU: A1043) is supplied as a solid for enhanced stability. Reconstitution should be performed with sterile water, ethanol, or DMSO depending on application requirements. For cell-based assays, a working concentration range of 10–100 nM is typical (t7-tag.com guide). The peptide should be stored desiccated at -20°C and protected from repeated freeze-thaw cycles. For in vivo studies, dosing regimens should be validated for each species and endpoint. The product’s high solubility allows for precise dosing and minimization of vehicle effects. The A1043 kit is compatible with a variety of cardiovascular and neuroendocrine assay formats (APExBIO product page). Compared to traditional RAAS peptides, Angiotensin III supports advanced experimental designs, including troubleshooting of receptor-specific responses and adaptation to viral pathogenesis models (angiotensin-ii.com perspective).

For a broader perspective on translational and troubleshooting applications, see "A Translational Keystone for Next-Generation RAAS Research", which contrasts Angiotensin III's unique value by integrating current mechanistic insights not covered in standard protocols.

Conclusion & Outlook

Angiotensin III (human, mouse) is a core peptide for dissecting RAAS function and receptor-specific signaling in cardiovascular and neuroendocrine research. APExBIO's A1043 formulation offers superior solubility, validated activity, and workflow versatility. Its dual receptor targeting and robust pressor and aldosterone-stimulating effects enable advanced modeling of disease and therapeutic pathways. As new evidence emerges—especially regarding viral pathogenesis and AT2-specific signaling—Angiotensin III is poised to remain central in both basic and translational research. For detailed product specifications and ordering, visit the Angiotensin III (human, mouse) product page.